The American Diabetes Association Scientific Sessions, held in June, featured cutting-edge science, from new agents to treat ...

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Amgen in November said MariTide helped patients with obesity lose up to 20% of their weight on average after a year in a phase two trial, with no weight loss plateau. The drug also helped patients ...

Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...

If MariTide demonstrates strong efficacy and safety profiles in its ongoing clinical trials, it could become a game-changer for Amgen. The obesity market is large and growing, with significant ...

--Amgen today announced full results from Part 1 of the Phase 2 study for MariTide in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the ...

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.

For the full year, Amgen slightly raised its financial outlook to adjusted earnings per share of $20.20 to $21.30 on revenue of $35 billion to $36 billion. It had previously forecast earnings of ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea. The drug demonstrated 20% average ...

Amgen investors are focused on prospects for MariTide, which activates the appetite- and blood sugar-reducing hormone known as GLP-1 while blocking a second gut hormone called GIP. The drug, given ...

THOUSAND OAKS, Calif., June 18, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study for MariTide (maridebart cafraglutide, formerly AMG 133) in ...